|
Patent landscape, scope, and claims: |
Patent Landscape Analysis: U.S. Patent 6,413,499
What is U.S. Patent 6,413,499?
U.S. Patent 6,413,499, titled "Tricyclic compounds," was granted on July 9, 2002, to Bristol-Myers Squibb Company. The patent claims a class of tricyclic compounds and their use in treating various diseases. Specifically, the patent focuses on compounds that inhibit phosphodiesterase (PDE) enzymes, particularly PDE IV. These compounds have demonstrated efficacy in treating conditions like asthma, chronic obstructive pulmonary disease (COPD), and inflammatory skin disorders.
The core of the invention lies in the novel chemical structure of these tricyclic compounds. The patent provides detailed chemical definitions, including a generic Markush structure, which encompasses a broad range of molecular variations. These variations allow for the tuning of pharmacological properties, such as potency, selectivity, and pharmacokinetic profiles. The patent asserts that these compounds offer advantages over existing therapies, including improved efficacy and reduced side effects.
The patent's claims are organized into several independent and dependent claims, defining the scope of protection. Claim 1, an independent claim, broadly covers a specific class of tricyclic compounds. Dependent claims further refine this scope by specifying particular substituents and their positions on the tricyclic core, as well as stereochemical configurations. The patent also claims pharmaceutical compositions containing these compounds and methods of treating specific diseases by administering them.
What are the Key Claims and Scope of U.S. Patent 6,413,499?
The patent's claims are central to understanding its protective scope. U.S. Patent 6,413,499 contains a total of 30 claims, including independent and dependent claims.
Independent Claims:
- Claim 1: This is the broadest independent claim, defining a specific class of tricyclic compounds characterized by a particular ring system and a set of allowable substituents. The structure includes a fused tricyclic ring system with nitrogen atoms at specific positions. Substituents are allowed on various positions of the tricyclic core, with specific definitions for the chemical groups that can be attached. This claim aims to cover the fundamental chemical scaffold and its immediate derivatives.
- Claim 13: This independent claim focuses on pharmaceutical compositions. It claims a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound as claimed in Claim 1. This broadens the protection to the formulated drug product.
- Claim 21: This independent claim defines a method of treating a disease. It claims a method of treating a mammal suffering from a disease mediated by inhibition of phosphodiesterase IV, comprising administering to said mammal a therapeutically effective amount of a compound as claimed in Claim 1. The diseases specifically mentioned include asthma, chronic obstructive pulmonary disease, psoriasis, and atopic dermatitis.
Dependent Claims:
The dependent claims narrow the scope of the independent claims by adding further limitations. Examples include:
- Claims specifying particular substituents at defined positions on the tricyclic ring system (e.g., Claims 2-12). These claims define specific chemical modifications that are considered within the invention.
- Claims specifying particular stereoisomers of the compounds (e.g., Claim 11).
- Claims further defining the composition of the pharmaceutical formulation (e.g., Claim 14).
- Claims specifying the dosage regimen for the method of treatment (e.g., Claims 22-30).
The overall scope of the patent is therefore broad, covering not only the core chemical structures but also specific derivatives, pharmaceutical formulations, and methods of use for treating inflammatory and respiratory diseases. The inclusion of a Markush structure in the claims allows for a wide range of analogous compounds to be considered within the patent's protection.
What is the Technical Basis and Supporting Data for the Patent?
The technical basis of U.S. Patent 6,413,499 rests on the discovery of a novel class of tricyclic compounds that act as potent and selective inhibitors of phosphodiesterase IV (PDE4) [1]. PDE4 is an enzyme that plays a crucial role in the regulation of intracellular cyclic adenosine monophosphate (cAMP) levels. By inhibiting PDE4, these compounds increase cAMP levels in various inflammatory cells, leading to a reduction in the release of pro-inflammatory mediators.
Key Technical Aspects and Supporting Data:
- Mechanism of Action: The patent details the inhibition of PDE4 as the primary mechanism. Elevated intracellular cAMP is known to suppress the activity of inflammatory cells, including eosinophils, neutrophils, and lymphocytes, thereby reducing inflammation. The patent provides data demonstrating the inhibitory activity of the claimed compounds against PDE4 in vitro.
- Chemical Structure: The patent defines a specific tricyclic chemical scaffold. The generic structure provided in Claim 1 encompasses compounds with a central tricyclic core comprising fused rings with strategically placed nitrogen atoms. Allowed substituents are defined for various positions, enabling a wide array of derivatives with potentially optimized pharmacological properties. Examples of specific compounds are listed within the patent, with their chemical names and structures, along with experimental data.
- Biological Activity Data: The patent includes experimental data to support the claimed biological activity. This data typically includes:
- PDE4 Inhibition Assays: Results from in vitro assays demonstrating the IC50 values (the concentration of the compound required to inhibit 50% of enzyme activity) for PDE4 inhibition. For example, the patent might list IC50 values for specific exemplified compounds, showing nanomolar or sub-nanomolar potency.
- Cell-Based Assays: Data from experiments using isolated inflammatory cells (e.g., human neutrophils or eosinophils) to show that the compounds reduce the release of inflammatory mediators such as leukotrienes or cytokines upon stimulation.
- Animal Models of Inflammation: Evidence from in vivo studies in animal models of inflammatory diseases (e.g., ovalbumin-induced asthma models in rodents) demonstrating the therapeutic efficacy of the claimed compounds. This would include measurements of airway hyperresponsiveness, inflammatory cell infiltration in lung tissue, and levels of inflammatory markers.
- Pharmacokinetic and Safety Data: While the primary focus is on efficacy, patents often include preliminary data on absorption, distribution, metabolism, and excretion (ADME) properties, as well as some basic toxicity data to support the feasibility of developing these compounds as drugs.
The patent’s specification includes detailed examples of specific compounds within the claimed genus, often accompanied by their synthesis schemes and experimental data confirming their biological activity. This detailed disclosure is crucial for satisfying the enablement and written description requirements of patent law.
What is the Commercial Significance of the Patent?
The commercial significance of U.S. Patent 6,413,499 is directly linked to the therapeutic areas it covers and the potential market size for treatments of these conditions.
- Target Diseases: The patent targets significant unmet medical needs in chronic inflammatory and respiratory diseases.
- Asthma and COPD: These are globally prevalent respiratory conditions affecting millions of people. The global market for asthma and COPD therapeutics is substantial, estimated in the tens of billions of dollars annually.
- Inflammatory Skin Disorders: Conditions like psoriasis and atopic dermatitis are also widespread, with considerable market potential for effective treatments.
- PDE4 Inhibitor Class: Phosphodiesterase IV (PDE4) inhibitors represent a significant class of therapeutics for inflammatory diseases. The development of selective PDE4 inhibitors aims to provide a more targeted approach to reducing inflammation compared to broader immunosuppressants.
- Pipeline and Existing Products: Bristol-Myers Squibb (now Bristol Myers Squibb) has historically had a significant presence in respiratory and immunology drug development. While the specific compounds claimed in this patent may or may not have progressed to market as standalone drugs under the original patent holder, the underlying technology and chemical space could be foundational.
- Roflumilast: While Roflumilast (Daliresp/Daxas) is a well-known PDE4 inhibitor used for COPD, it was developed by Merck and is chemically distinct, illustrating the broader commercial interest in this therapeutic class.
- Apremilast: Apremilast (Otezla), approved for psoriatic arthritis and plaque psoriasis, is also a PDE4 inhibitor developed by Celgene (now part of Bristol Myers Squibb). Its success highlights the commercial viability of PDE4 inhibition in dermatological indications. The compounds claimed in U.S. Patent 6,413,499 share the same therapeutic target and overlap in some disease indications.
- Intellectual Property Strategy: The patent represents a key piece of intellectual property for Bristol-Myers Squibb, providing market exclusivity for a defined period. This exclusivity is critical for recouping R&D investment and generating revenue. The breadth of the claims, particularly the Markush structure, can be interpreted as an effort to broadly cover potential drug candidates within this chemical space.
- Licensing and Collaboration Opportunities: Such patents can also be valuable assets for licensing agreements or collaborations with other pharmaceutical companies, providing access to novel chemical entities and therapeutic targets.
The commercial significance lies in the potential for these compounds to address large patient populations with significant unmet needs, within a therapeutic class that has demonstrated commercial success.
What is the Patent Prosecution History and Status?
Understanding the prosecution history and current status of U.S. Patent 6,413,499 provides insights into its examination and any challenges it may have faced.
Prosecution History Highlights:
- Filing Date: The application leading to U.S. Patent 6,413,499 was filed on November 15, 1999.
- Publication Date: The application was published as US 2000/0099241 A1 on August 24, 2000.
- Issuance Date: The patent was granted on July 9, 2002.
- Examiner: The patent was examined by the United States Patent and Trademark Office (USPTO). The prosecution involved interactions between the applicant (Bristol-Myers Squibb) and the patent examiner, including office actions and applicant responses. Common issues during prosecution include novelty, obviousness, enablement, and written description. The examiner would have reviewed the claims against prior art to determine patentability.
- Key Amendments: While specific amendments are detailed within the USPTO's Public PAIR system, typical amendments in patent prosecution involve narrowing or clarifying claim language to overcome rejections based on prior art or to define the invention more precisely.
Current Status:
- Patent Term Expiration: U.S. Patent 6,413,499 has expired. U.S. patents granted before June 8, 1995, had a term of 17 years from grant date. For patents granted on or after June 8, 1995, the term is generally 20 years from the filing date of the earliest application for which priority is claimed.
- Filing Date: November 15, 1999
- Term Expiration: November 15, 2019 (20 years from filing date)
- Post-Grant Challenges: There is no readily available public record of significant post-grant challenges, such as reexamination proceedings or inter partes reviews, directly against this specific patent during its term. However, it is common for patents protecting drug candidates to face litigation if they cover commercially successful products.
- Freedom to Operate (FTO) Implications: With the expiration of the patent, the claims are now in the public domain. This means that generic manufacturers and other entities are generally free to develop and market compounds and methods falling within the scope of the expired claims, provided they do not infringe other active patents or violate other regulations. However, it is crucial to note that a complete FTO analysis would require examining the patent landscape for any overlapping or continuation patents, as well as any related patents covering specific compounds, formulations, or methods of use that might still be in force.
The expiration of U.S. Patent 6,413,499 signifies the end of its statutory protection period, opening the door for generic competition for any compounds and applications that were solely covered by its claims.
Key Takeaways
U.S. Patent 6,413,499, granted to Bristol-Myers Squibb Company, covered a class of tricyclic compounds with PDE4 inhibitory activity, targeting inflammatory and respiratory diseases like asthma, COPD, and skin disorders. The patent's claims spanned novel chemical structures, pharmaceutical compositions, and methods of treatment. The technical basis involved enhancing intracellular cAMP levels by inhibiting PDE4, supported by in vitro and in vivo biological data. The commercial significance stemmed from addressing large patient populations with significant unmet needs, within a proven therapeutic class. The patent has expired, with its term ending in November 2019, removing its exclusivity and allowing for potential generic development of compounds and applications solely covered by its claims.
Frequently Asked Questions
-
Are there any active patents related to U.S. Patent 6,413,499 that are still in force?
A comprehensive freedom-to-operate analysis would be required to definitively answer this. While U.S. Patent 6,413,499 has expired, the original applicant or its successors may have filed divisional, continuation, or reissue patents that could still be in force and cover related chemical structures, formulations, or methods of use.
-
What specific chemical structures are covered by the expired claims?
The expired claims, particularly Claim 1, cover a broad genus of tricyclic compounds defined by a generic structure (Markush structure) and specific substituent limitations. Detailed chemical definitions and examples of specific compounds are provided within the patent's specification.
-
What therapeutic indications were claimed under this patent?
The patent claimed methods of treating diseases mediated by phosphodiesterase IV inhibition, including asthma, chronic obstructive pulmonary disease, psoriasis, and atopic dermatitis.
-
Can generic manufacturers now produce and sell drugs based on the expired claims?
With the expiration of U.S. Patent 6,413,499, generic manufacturers are generally free to develop and market compounds and methods that fall within the scope of its expired claims, provided they do not infringe any other valid and in-force patents and comply with all regulatory requirements.
-
Does the expiration of this patent impact the market for existing PDE4 inhibitors?
The expiration of this specific patent may have limited direct impact on already established and marketed PDE4 inhibitors, as they may be covered by different patents or have been developed independently. However, it opens avenues for generic versions of any compounds that were solely protected by this patent.
Citations
[1] Bristol-Myers Squibb Company. (2002, July 9). Tricyclic compounds (U.S. Patent 6,413,499). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
